TY - JOUR
T1 - Virus-Like Particles as Preventive and Therapeutic Cancer Vaccines
AU - Tornesello, Anna Lucia
AU - Tagliamonte, Maria
AU - Buonaguro, Franco M.
AU - Tornesello, Maria Lina
AU - Buonaguro, Luigi
N1 - Funding Information:
Funding: This research was funded by the Italian Ministry of Health through Institutional “Ricerca Corrente” (LB); POR FESR 2014/2020 “Campania OncoTerapie” (LB).
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2
Y1 - 2022/2
N2 - Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the native virus structure without being infectious. VLPs, similarly to wild type viruses, are able to effi-ciently target and activate dendritic cells (DCs) triggering the B and T cell immunities. Therefore, VLPs hold great promise for the development of effective and affordable vaccines in infectious diseases and cancers. Vaccine formulations based on VLPs, compared to other nanoparticles, have the advantage of incorporating multiple antigens derived from different proteins. Moreover, such antigens can be functionalized by chemical modifications without affecting the structural conformation or the antigenicity. This review summarizes the current status of preventive and therapeutic VLP-based vaccines developed against human oncoviruses as well as cancers.
AB - Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the native virus structure without being infectious. VLPs, similarly to wild type viruses, are able to effi-ciently target and activate dendritic cells (DCs) triggering the B and T cell immunities. Therefore, VLPs hold great promise for the development of effective and affordable vaccines in infectious diseases and cancers. Vaccine formulations based on VLPs, compared to other nanoparticles, have the advantage of incorporating multiple antigens derived from different proteins. Moreover, such antigens can be functionalized by chemical modifications without affecting the structural conformation or the antigenicity. This review summarizes the current status of preventive and therapeutic VLP-based vaccines developed against human oncoviruses as well as cancers.
KW - Antigen delivery
KW - Cancer vaccine
KW - EBV
KW - Epstein–Barr virus
KW - HBV
KW - Hepatitis B
KW - HHV8
KW - HPV
KW - Human herpesvirus type 8
KW - Human papillomavirus
KW - Virus-like particles
KW - VLPs
UR - http://www.scopus.com/inward/record.url?scp=85124083795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124083795&partnerID=8YFLogxK
U2 - 10.3390/vaccines10020227
DO - 10.3390/vaccines10020227
M3 - Review article
AN - SCOPUS:85124083795
SN - 2076-393X
VL - 10
JO - Vaccines
JF - Vaccines
IS - 2
M1 - 227
ER -